Gilead Raises Its Product Sales Forecast, Beats on Earnings

(Bloomberg) -- Gilead Sciences Inc. raised its outlook for product sales in the second quarter, even as the biotechnology company fights off slipping sales of its blockbuster hepatitis C franchise.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.